DESTINY-Breast02

The study is designed to compare DS 8201a versus standard of care (investigator’s choice) in subjects with unresectable and/or metastatic breast cancer previously treated with T-DM1.

Acronym:

Daiichi

ACTRN/NCT /ethics:

NCT03523585

Scientific title:

A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study of Trastuzumab Deruxtecan (DS-8201a), an Anti-HER2-antibody Drug Conjugate, Versus Treatment of Investigator’s Choice for HER2-positive, Unresectable and/or Metastatic Breast Cancer Subjects Pretreated With Prior Standard of Care HER2 Therapies, Including T-DM1

Sponsor / Cooperative group:

Daiichi Sankyo, Inc.